In the SURMOUNT program (SM), treatment with tirzepatide led to a significant and clinically meaningful reduction in body weight (BW) in overweight and obese subjects. In a post-hoc analysis, the effect of tirzepatide treatment on body weight in women was examined according to the stage of menopause.
Autoren
- Jens Dehn
Publikation
- InFo DIABETOLOGIE & ENDOKRINOLOGIE
Related Topics
You May Also Like
- Oncology
Study updates from the ESMO Congress
- High-dose influenza vaccine
Lower hospitalization rates – even with heart failure
- From statins to metformin
Preventive pharmacology and longevity
- Important basics and studies on cancer and the psyche
Interplay between cancer and mental illness
- From symptom to diagnosis
Abdominal pain – angiosarcoma
- Pediatric epilepsy
Diazepam nasal spray for infants
- Findings from research on the generalization of exposure therapy
Treatment of comorbid anxiety
- Symptom-free despite asthma?